<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607096</url>
  </required_header>
  <id_info>
    <org_study_id>596/2020BO1</org_study_id>
    <nct_id>NCT04607096</nct_id>
  </id_info>
  <brief_title>Intermittent Fasting to Improve Insulin Secretion</brief_title>
  <acronym>IFIS</acronym>
  <official_title>Intermittent Fasting to Improve Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Institute of Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Diabetes-Center, Leibniz-Institut in DÃ¼sseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Diabetes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes (T2D) mellitus is a challenge for health care systems as the numbers&#xD;
      increases constantly. In 2014, 422 million people had been living with diabetes worldwide.&#xD;
      The absolute numbers of people with prediabetes have also grown substantially over 25 years&#xD;
      worldwide. In Germany, about 10% of the population has T2D and another 21 % of the population&#xD;
      has prediabetes.Overall, 16% of all deaths in Germany are attributable to type 2 diabetes.&#xD;
      Macro- and microvascular complications of diabetes imply a significant threat for the&#xD;
      patients and are already present in the prediabetic state. Short term and long term&#xD;
      complications, the burden of treatment, and reduced quality of life are major burdens of the&#xD;
      disease. Accumulating data indicate that currently recommended therapeutic diet regimens in&#xD;
      patients with obesity and diabetes are not sustainable on the long term. Novel concepts are&#xD;
      therefore urgently needed.&#xD;
&#xD;
      T2D occurs when insulin secretion from pancreatic beta-cells cannot sufficiently be increased&#xD;
      to compensate for insulin resistance. Causes of beta-cell dysfunction are heterogeneous. In&#xD;
      addition, the most important determinants of diabetes remission are the extend of weight loss&#xD;
      and restoration of beta-cell function. In the course of diabetes progression, the inability&#xD;
      to recover insulin secretion might identify the state of no return to normal glucose&#xD;
      tolerance. It is therefore crucial to improve insulin secretion in treatment and prevention&#xD;
      of diabetes. Up to now lifestyle intervention trials in prediabetes or pharmacological&#xD;
      intervention trials in diabetes did not show improvement of insulin secretion after&#xD;
      intervention. However, one recent small human trial shows that intermittent fasting (early&#xD;
      time restricted fasting) is able to improve insulin secretion.Currently, there are no trials&#xD;
      that examine the effect of intermittent fasting in individuals with a broad range of impaired&#xD;
      glucose metabolism (from prediabetes to diabetes). Recently novel subtypes of diabetes and&#xD;
      prediabetes with high risk for the early manifestation of diabetes complications have been&#xD;
      identified. Currently, prevention strategies for this high risk individuals have not been&#xD;
      examined yet. We will study for the first time the effectiveness of 4 weeks intermittent&#xD;
      fasting on changes in insulin secretion capacity in subphenotypes of diabetes and in&#xD;
      prediabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants wil either receive a control diet or join the intermittent fasting group stratified by glycemia (prediabetes/diabetes) as well as by subphenotype.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in first phase insulin secretion.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent fasting vs. a control diet on glucose stimulated first phase insulin secretion adjusted for insulin sensitivity during an hyperglycemic clamp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in second phase insulin secretion.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent fasting vs. a control diet on glucose stimulated second phase insulin secretion adjusted for insulin sensitivity during an hyperglycemic clamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent fasting vs. a control diet on insulin sensitivity using insulin sensitivity index during an hyperglycemic clamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent vs. a control diet fasting on BMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver fat content.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on liver fat content (%) measured by magnetic resonance spectroscopy (3 T whole body imaging).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pancreatic fat content.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting on pancreatic fat content (%) measured by magnetic resonance spectroscopy (3 T whole body imaging).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat content.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on total adipose tissue (TAT) measured by magnetic resonance tomography (3 T whole body imaging).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on visceral adipose tissue (VAT) measured by by magnetic resonance tomography (3 T whole body imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subcutaneous adipose tissue.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on subcutaneous adipose tissue (SCAT) measured by by magnetic resonance tomography (3 T whole body imaging)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in brain insulin sensitivity.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on brain insulin sensitivity measured by functional magnetic resonance imaging (fMRI) combined with nasal insulin administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in resting energy expenditure (REE).</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on resting energy expenditure measured by indirect calorimetry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in substrate oxidation.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effects of intermittent fasting vs. a control diet on substrate oxidation measured by indirect calorimetry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in proinsulin processing.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent fasting vs. a control diet on first phase proinsulin processing during an hyperglycemic clamp.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in glucagon suppression.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent fasting vs. a control diet on glucagon suppression during an hyperglycemic clamp.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in insuin clearance.</measure>
    <time_frame>Before, after 4 weeks and after 24 weeks of lifestyle intervention.</time_frame>
    <description>Effect of intermittent fasting vs. a control diet on insulin clearance during an hyperglycemic clamp.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Diabetes type2</condition>
  <condition>Intermittent Fasting</condition>
  <condition>Insulin Secretion</condition>
  <arm_group>
    <arm_group_label>Prediabetic subjects - cluster 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetic subjects - cluster 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Presence of a cluster 5 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intermittent fasting</intervention_name>
    <description>The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.</description>
    <arm_group_label>Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)</arm_group_label>
    <arm_group_label>Prediabetic subjects - cluster 3</arm_group_label>
    <arm_group_label>Prediabetic subjects - cluster 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control diet</intervention_name>
    <description>Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)</description>
    <arm_group_label>Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)</arm_group_label>
    <arm_group_label>Prediabetic subjects - cluster 3</arm_group_label>
    <arm_group_label>Prediabetic subjects - cluster 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between 25 - 40 kg/mÂ²&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent document prior to any study&#xD;
             related assessments/procedures.&#xD;
&#xD;
          -  Subjects with prediabetes (IFG and/or IGT, HbA1c 5,4 % - 6,4 %, subphenotype cluster 3&#xD;
             or 5) or&#xD;
&#xD;
          -  Subjects with diabetes mellitus type 2 (diagnosis &lt; 1 year, HbA1c = 6,5 - 9 %, no&#xD;
             medical treatment, subphenotype SIDD or SIRD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with diabetes mellitus type 1 (GAD-, IA2-AB positive)&#xD;
&#xD;
          -  Women during pregnancy and lactation&#xD;
&#xD;
          -  Treamtent with any medication effecting on glucose metabolism like anti-diabetic drugs&#xD;
             or steroids&#xD;
&#xD;
          -  Subjects with a haemoglobin (Hb) â¤ 11.5 g/dl (for males) and Hb â¤ 10.5 g/dl (for&#xD;
             females) at screening&#xD;
&#xD;
          -  Any pancreatic disease&#xD;
&#xD;
          -  Medical history of cancer and/or treatment for cancer within the last 5 years.&#xD;
&#xD;
          -  Known current presence or history of severe neurological or psychiatric diseases,&#xD;
             schizophrenia, bipolar disorder&#xD;
&#xD;
          -  Known history of bariatric surgery&#xD;
&#xD;
          -  Severe liver or kidney diseases (Alanine Aminotransferase (ALT [SGPT]), Aspartate&#xD;
             Aminotransferase (AST [SGOT]) above 3 x upper limit of normal (ULN) or Glomerular&#xD;
             Filtration Rate (eGFR) â¤ 60 ml/min (MDRD formula)&#xD;
&#xD;
          -  Systemic infection (CRP &gt; 1 mg/dl)&#xD;
&#xD;
          -  Severe diabetic complications like chronic kidney disease (CKD), proliferating&#xD;
             retinopathy or symptomatic cardiovascular disease&#xD;
&#xD;
          -  Presence of any contraindication for the conduct of an MRI investigation, such as&#xD;
             cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system,&#xD;
             metallic splinters in the eye, ferromagnetic or electronically operated active devices&#xD;
             like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve&#xD;
             stimulators, prosthetic heart valves etc.&#xD;
&#xD;
          -  Persons with limited temperature sensation and / or elevated sensitivity to warming of&#xD;
             the body&#xD;
&#xD;
          -  Persons with a hearing disorder or a increased sensitivity for loud noises&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Participation in other clinical trials or observation period of competing trials up to&#xD;
             30 days prior to this study&#xD;
&#xD;
          -  Refusal to get informed of unexpected detected pathological findings&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Fritsche, MD</last_name>
    <phone>+49 7071 29 80590</phone>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Roden, MD</last_name>
    <phone>+49 211 3382 201</phone>
    <email>michael.roden@ddz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CharitÃ© Berlin - Department of Endocrinology and Metabolic Diseases</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joachim Spranger, MD</last_name>
      <phone>+49 30 450 514 252</phone>
      <email>joachim.spranger@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Schwarz, MD</last_name>
      <phone>+49 (0) 351 458271</phone>
      <email>peter.schwarz@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Roden, MD</last_name>
      <phone>+49 211 3382 201</phone>
      <email>michael.roden@ddz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital - Department of Endocrinology and Metabolism</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia SzendrÃ¶di, MD</last_name>
      <phone>+49 (0) 6221 56-8601</phone>
      <email>Julia.SzendrÃ¶di@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig - Clinic for Endocrinology and Nephrology</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias BlÃ¼her, MD</last_name>
      <phone>+49 (0)341 - 97 13320</phone>
      <email>Matthias.blÃ¼her@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Luebeck - Institute of Endocrinology and Diabetes</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Schmid, MD</last_name>
      <email>Sebastian.Schmid@uni-luebeck.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich - Else Kroener-Fresenius-Center for Nutritional Medicine</name>
      <address>
        <city>Munich</city>
        <zip>80992</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Hauner, MD</last_name>
      <phone>+49 (0) 8928924911</phone>
      <email>hans.hauner@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen - Institute for Diabetes Research and Metabolic Diseases (IDM)</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Fritsche, MD</last_name>
      <phone>+49 7071 29 80590</phone>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

